Zinforo Dosage/Direction for Use

Posology: The recommended durations of treatment are 5-14 days for cSSTI and 5-7 days for CAP. (See Tables 11 and 12.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Special populations: Elderly: No dosage adjustment is required for the elderly with creatinine clearance values >50 mL/min (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: The dose should be adjusted when creatinine clearance (CrCL) is ≤50 mL/min, as shown in Tables 13 and 14 (see Overdosage and Pharmacology: Pharmacokinetics under Actions). The recommended durations of treatment are 5-14 days for cSSTI and 5-7 days for CAP. (See Table 13.)

Click on icon to see table/diagram/image

Dose recommendations for neonates, infants and children and adolescents are based on pharmacokinetic (PK) modelling.
There is insufficient information to recommend dosage adjustments in adolescents aged from 12 to <18 years with bodyweight <33 kg and in children aged from 2 to 12 years with End-stage renal disease (ESRD).
There is insufficient information to recommend dosage adjustments in paediatric patients <2 years with moderate or severe renal impairment or ESRD. (See Table 14.)

Click on icon to see table/diagram/image

Hepatic impairment: No dosage adjustment is considered necessary in patients with hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: Intravenous use. Zinforo is administered by intravenous infusion over 5 to 60 minutes for standard dose or 120 minutes for high dose (for cSSTI caused by S. aureus with MIC of 2 or 4 mg/L to ceftaroline) in infusion volumes of 50 mL, 100 mL or 250 mL (see Special precautions for disposal and other handling under Cautions for Usage). Infusion related reactions (such as phlebitis) can be managed by prolonging the infusion duration.
Infusion volumes for paediatric patients will vary according to the weight of the child. The infusion solution concentration during preparation and administration should not exceed 12 mg/mL ceftaroline fosamil.
For instructions on reconstitution and dilution of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.